Lansforsakringar Fondforvaltning Ab (Publ) Alnylam Pharmaceuticals, Inc. Transaction History
Lansforsakringar Fondforvaltning Ab (Publ)
- $17 Billion
- Q2 2025
A detailed history of Lansforsakringar Fondforvaltning Ab (Publ) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Lansforsakringar Fondforvaltning Ab (Publ) holds 40,231 shares of ALNY stock, worth $17.8 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
40,231
Previous 42,303
4.9%
Holding current value
$17.8 Million
Previous $11.4 Million
14.85%
% of portfolio
0.08%
Previous 0.07%
Shares
3 transactions
Others Institutions Holding ALNY
# of Institutions
830Shares Held
118MCall Options Held
584KPut Options Held
648K-
Capital World Investors Los Angeles, CA16.8MShares$7.44 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$6.01 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.23 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.18 Billion0.49% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.01 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $54.5B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...